Tirzepatide Research
Frias 2021 — SURPASS-2 Tirzepatide vs Semaglutide T2D
New England Journal of Medicine·June 25, 2021
Juan Pablo Frias, Melanie J. Davies, Julio Rosenstock, Federico C. Pérez Manghi, Laura Fernández Landó, Brenda K. Bergman, Bo Liu, Xuewei Cui, Katelyn Brown
Summary
Tirzepatide was noninferior and superior to semaglutide for HbA1c reduction. Weight reductions were greater with tirzepatide (-1.9 to -5.5 kg difference). Tirzepatide 15mg achieved nearly twice the weight loss.
Study Details
Study Design
Phase 3 open-label head-to-head
Indication
Type 2 diabetes
Intervention
Tirzepatide vs semaglutide
Species
Human
Sample Size
1,879 subjects
Risk of Bias Assessment
Open-label; sponsor-funded
Tags
SourcePhase 3SurpassT2DHead to HeadTirzepatideSemaglutide